Annexes to the recommendations for use of the Janssen AD26.COV2.S vaccine against COVID-19

Grading of evidence -Evidence to recommendations tables First issued 17 March 2021 Updated 15 June 2021 Updated 9 December 2021



Background

These are the annexes to the Interim recommendations for use of the Janssen AD26.COV2.S vaccine.

Annexes 1–6 contain tables that summarize the grading of recommendations, assessment, development and evaluations (GRADE). Annexes 7–9 contain the SAGE evidence-to-recommendation framework tables (ETR tables). The ETR tables are based on the DECIDE Work Package 5: Strategies for communicating evidence to inform decisions about health system and public health interventions. Evidence to a recommendation (for use by a guideline panel) (www.decide-collaboration.eu/, accessed 9 December 2021).

Contents

Annex 1. GRADE table: Efficacy of Janssen AD26.COV2.S COVID-19 vaccine in adults	2
Annex 2. GRADE table: Safety of Janssen AD26.COV2.S COVID-19 vaccine in adults	
Annex 3. GRADE table: Efficacy of Janssen AD26.COV2.S COVID-19 vaccine in older adults	3
Annex 4. GRADE table: Safety of vaccine in older adults	. 5
Annex 5. GRADE table: GRADE table: Efficacy of Janssen AD26.COV2.S COVID-19 vaccine in individuals with	
underlying conditions	. 6
Annex 6. GRADE table: Safety of Janssen AD26.COV2.S COVID-19 vaccine in individuals with underlying	
conditions	
Annex 7. SAGE evidence-to-recommendation framework: Janssen AD26.COV2.S vaccine use in adults	. 8
Annex 8. SAGE evidence-to-recommendation framework: Janssen AD26.COV2.S vaccine use in older adults	17
Annex 9. SAGE evidence-to-recommendation framework: Janssen AD26.COV2.S vaccine use in individuals with	
comorbidities	26

Population:	Adults (18–59 years)	
Intervention:	Single dose of Janssen AD26.COV2.S vaccine	
Comparison:	Placebo/active control	
Outcome:	Moderate to severe/critical COVID-19 (PCR-confirmed)	

What is the efficacy of a single dose of Janssen AD26.COV2.S vaccine compared with placebo/active control in preventing moderate to severe/critical PCR-confirmed COVID-19 in adults (18–59 years)?

			Rating	Adjustment to rating
	No. of studies/starting rating		1/ RCT <i>(1)</i>	4
		Limitation in study design ^a	Not serious	0
	Factors	Inconsistency	Not serious	0
	decreasing confidence	Indirectness	Not serious	0
	connucrice	Imprecision	Not serious	0
nent		Publication bias	Not serious	0
usse		Large effect	Not applicable	0
Asse	Factors increasing	Dose-response	Not applicable	0
Quality Assessment	confidence	Antagonistic bias and confounding	Not applicable	0
0	Final numerical rating of quality of evidence		of evidence	4
of	Statement on quality of evidence			Evidence supports a high level of confidence that the true effect lies close to the estimate of the effect on the health outcome (level 4).
Summary of Findings	Conclusion			We are very confident that a single dose of Janssen AD26.COV2.S vaccine is efficacious in preventing moderate to severe/critical PCR-confirmed COVID-19 in adults (18–59 years).

^a For the risk of bias assessments using the revised Cochrane risk-of-bias tool for randomized trials (RoB 2), please see <u>www.covid-nma.com/vaccines</u>.

Annex 2. GRADE table: Safety of Janssen AD26.COV2.S COVID-19 vaccine in adults

Population:	Adults (18–59 years)
Intervention:	Single dose of Janssen AD26.COV2.S vaccine
Comparison:	Placebo/active control
Outcome:	Serious adverse events following immunization

What is the risk of serious adverse events following Janssen AD26.COV2.S vaccination compared with placebo/active control in adults (18–59 years)?

			Rating	Adjustment to rating
	No. of studies/starting rating		2/ RCT (1, 2)	4
	Factors	Limitation in study design ^a	Serious ^b	-1
		Inconsistency	Not serious	0
	decreasing confidence	Indirectness	Not serious	0
	Connucinoe	Imprecision	Not serious	0
nent		Publication bias	Not serious	0
usse		Large effect	Not applicable	0
Quality Assessment	Factors increasing	Dose-response	Not applicable	0
	confidence	Antagonistic bias and confounding	Not applicable	0
	Final numerical rating of quality of evidence			3
Findings	Statement on quality of evidence			Evidence supports a moderate level of confidence that the true effect lies close to the estimate of the effect on the health outcome (level 3).
Summary of Findings	Conclusion			We are moderately confident that there is a very low risk of serious adverse events (Thrombosis with Thrombocytopenia Syndrome) following a single dose of Janssen AD26.COV2.S vaccine in adults (18–59 years).

Annex 3. GRADE table: Efficacy of Janssen AD26.COV2.S COVID-19 vaccine in older adults

Population: Older adults (\geq 60 years)

^a For the risk of bias assessments using the revised Cochrane risk-of-bias tool for randomized trials (RoB 2), please see <u>www.covid-nma.com/vaccines</u>.

^b Downgraded for the following limitations. The trial was not adequately powered to detect rare adverse events (i.e. fewer than about 1 in 2000). Post-licensure data have identified the following safety signals following vaccination: a very rare syndrome of blood clotting combined with low platelet counts has been reported about 3 to 15 days following vaccination with the Ad26.COV2.S vaccine, described as Thrombosis with Thrombocytopenia Syndrome (TTS). Current evidence suggests a plausible causal association between the J&J COVID-19 vaccine and TTS. Further, Guillain-Barre Syndrome (GBS) and capillary leak syndrome (CLS) have been observed.. TTS was reported as one case in approximately 2 per million doses administered, GBS was reported as one case in 7-8 per million doses administered and CLS as 0.21 cases per million doses administered.

Intervention: Older adults (≥60 years)

Comparison: Single dose of Janssen AD26.COV2.S vaccine

Outcome: Moderate to severe/critical COVID-19 (PCR-confirmed)

What is the efficacy of a single dose of Janssen AD26.COV2.S vaccine compared with placebo/active control in preventing moderate to severe/critical PCR-confirmed COVID-19 in older adults (≥60 years)?

			Rating	Adjustment to rating
	No. of studies/starting rating		1/ RCT <i>(1)</i>	4
		Limitation in study design ^a	Not serious ^b	0
	Factors	Inconsistency	Not serious	0
	decreasing confidence	Indirectness	Not serious	0
		Imprecision	Not serious	0
nent		Publication bias	Not serious	0
usse	Factors increasing	Large effect	Not applicable	0
Asse		Dose-response	Not applicable	0
Quality Assessment	confidence	Antagonistic bias and confounding	Not applicable	0
	Final numerical rating of qua		of evidence	4
	Statement on quality of evidence			Evidence supports a high level of confidence that the true effect lies close to the estimate of the effect on the health outcome (level 4).
Summary of Findings				We are confident that a single dose of JANSSEN AD26.COV2.S vaccine is efficacious in preventing moderate to severe/critical PCR-confirmed COVID- 19 in older adults (≥60 years), though vaccine effectiveness may wane over time.

^a For the risk of bias assessments using the revised Cochrane risk-of-bias tool for randomized trials (RoB 2), please see www.covid-nma.com/vaccines.

^b Observational and immunogenicity data suggest a decline in vaccine effectiveness and neutralizing antibodies over time in older adults.

Annex 4. GRADE table: Safety of vaccine in older adults

Population:	Older adults (≥60 years)
Intervention:	Single dose of Janssen AD26.COV2.S vaccine
Comparison:	Placebo/active control
Outcome:	Serious adverse events following immunization

What is the risk of serious adverse events following Janssen AD26.COV2.S vaccination compared with placebo/active control in older adults (\geq 60 years)?

			Rating	Adjustment to rating
	No. of studies/starting rating		1/ RCT <i>(1, 2</i>)	4
		Limitation in study design ^a	Serious ^b	-1
	Factors	Inconsistency	Not serious	0
	decreasing	Indirectness	Not serious	0
		Imprecision	Not serious ^c	0
rent		Publication bias	Not serious	0
usse	Factors increasing confidence	Large effect	Not applicable	0
Asse		Dose-response	Not applicable	0
Quality Assessment		Antagonistic bias and confounding	Not applicable	0
Ŭ	Final nume	rical rating of quality o	of evidence	3
Findings	ଞ୍ଚ ଅ ଅ ଅ ଅ ଅ			Evidence supports a moderate level of confidence that the true effect lies close to the estimate of the effect on the health outcome (level 3).
Summary of Findings	Conclusion			We are moderately confident that the risk of serious adverse events following a single dose of Janssen AD26.COV2.S vaccine in older adults (≥60 years) is low.

^a For the risk of bias assessments using the revised Cochrane risk-of-bias tool for randomized trials (RoB 2), please see <u>www.covid-nma.com/vaccines</u>.

^b Downgraded for the following limitations. The trial was not adequately powered to detect rare adverse events (i.e. fewer than about 1 in 2000).

^c Approximately 40% of the trial participants were aged 60 years or over. This was not considered as constituting a limitation that leads to downgrading of the evidence.

Annex 5. GRADE table: Efficacy of Janssen AD26.COV2.S COVID-19 vaccine in individuals with underlying conditions

Population:	Individuals with comorbidities or health states that increase risk for severe COVID-19		
Intervention:	Single dose of Janssen AD26.COV2.S vaccine		
Comparison:	Placebo/active control		
Outcome:	Moderate to severe/critical COVID-19 (PCR-confirmed)		

What is the efficacy of a single dose of Janssen AD26.COV2.S vaccine compared with placebo/active control in preventing moderate to severe/critical PCR-confirmed COVID-19 in individuals with comorbidities or health states that increase risk for severe COVID-19?

	_		Rating	Adjustment to rating
	No. of studies/starting rating		1/ RCT <i>(1)</i>	4
		Limitation in study design ^a	Not serious	0
	Factors	Inconsistency	Not serious	0
	decreasing confidence	Indirectness	Serious ^b	-1
		Imprecision	Not serious ^c	0
ient		Publication bias	Not serious	0
SSIT		Large effect	Not applicable	0
Asse	Factors increasing	Dose-response	Not applicable	0
Quality Assessment	confidence	Antagonistic bias and confounding	Not applicable	0
	Final numerical rating of quality of		of evidence	3
	Statement on quality of evidence			Evidence supports a moderate level of confidence that the true effect lies close to the estimate of the effect on the health outcome (level 3).
Summary of Findings	Conclusion			We are moderately confident that a single dose of Janssen AD26.COV2.S vaccine is efficacious in preventing moderate to severe/critical PCR- confirmed COVID-19 in individuals with comorbidities or health states that increase risk for severe COVID-19, as included in the clinical trial. No data were obtained from the clinical trial on vaccination of pregnant or breastfeeding women, or persons who were immunocompromised.

^a For the risk of bias assessments using the revised Cochrane risk-of-bias tool for randomized trials (RoB 2), please see <u>www.covid-nma.com/vaccines</u>.

^b Trial excluded pregnant and breastfeeding women, and persons who were immunocompromised. This was considered as constituting a limitation that leads to downgrading of the evidence.

^c Underlying comorbidities included BMI \geq 30 kg/m2, cardiovascular disorder, respiratory disease and diabetes. Approximately 40% of the trial population had at least one comorbidity. This was considered as not constituting a limitation that would lead to downgrading of the evidence. Data on long-term protection emerging from the ongoing phase 3 clinical trial remain limited, as trial data have so far been reported only for a follow-up of approximately 2 months. This was considered as not constituting a limitation that would lead to downgrading of the evidence. SAGE will continue to review any emerging data and adjust its quality assessment as required.

Annex 6. GRADE table: Safety of Janssen AD26.COV2.S COVID-19 vaccine in individuals with underlying conditions

Population:	Individuals with comorbidities or health states that increase risk for severe COVID-19		
Intervention:	Single dose of Janssen AD26.COV2.S vaccine		
Comparison:	Placebo/active control		
Outcome:	Serious adverse events following immunization		

What is the risk of serious adverse events following Janssen AD26.COV2.S vaccination compared with placebo/active control in individuals with underlying conditions?

			Rating	Adjustment to rating
Quality Assessment	No. of studies/starting rating		1/ RCT <i>(1-3)</i>	4
	Factors decreasing confidence	Limitation in study design ^a	Serious ^b	-1
		Inconsistency	Not serious	0
		Indirectness	Serious ^c	0
		Imprecision	Not serious	0
		Publication bias	Not serious	0
	Factors increasing confidence	Large effect	Not applicable	0
		Dose-response	Not applicable	0
		Antagonistic bias and confounding	Not applicable	0
	Final numerical rating of quality of evidence			2
Summary of Findings	Statement on quality of evidence			Evidence supports a limited level of confidence that the true effect lies close to the estimate of the effect on the health outcome (level 2).
	Conclusion			We have low confidence in the quality of evidence that there is a low risk of serious adverse events (Thrombosis with Thrombocytopenia Syndrome) in individuals with comorbidities or health states that increase risk for severe COVID-19 following a single dose of Janssen AD26.COV2.S vaccine.

^a For the risk of bias assessments using the revised Cochrane risk-of-bias tool for randomized trials (RoB 2), please see www.covid-nma.com/vaccines.

^b Downgraded for the following limitations. The trial was not adequately powered to detect rare adverse events (i.e. fewer than about 1 in 2000). Post-licensure data have identified the following safety signals following vaccination: a very rare syndrome of blood clotting combined with low platelet counts has been reported about 3 to 15 days, , mainly in younger individuals (18-59 years) following vaccination with the Ad26.COV2.S vaccine, described as Thrombosis with Thrombocytopenia Syndrome (TTS), Current evidence suggests a plausible causal association between the J&J COVID-19 vaccine and TTS. Further, Guillain-Barre Syndrome (GBS) and capillary leak syndrome (CLS) have been observed. TTS was reported as one case in approximately 2 per million doses administered, GBS was reported as one case in 7-8 per million doses administered and CLS as 0.21 cases per million doses administered.

^c Trial excluded pregnant and breastfeeding women and persons who were immunocompromised. This was considered as constituting a limitation that leads to downgrading of the evidence.

Annex 7. SAGE evidence-to-recommendation framework: Janssen AD26.COV2.S vaccine use in adults

Question: Should Janssen AD26.COV2.S vaccine be administered to adults to prevent moderate to severe/critical COVID-19?

Population: Adults (18–59 years)

Intervention: Single dose of JANSSEN AD26.COV2.S vaccine

Comparison(s): Active control/placebo

Outcome: Moderate to severe/critical COVID-19 (PCR-confirmed)


Background: On 31 December 2019, WHO was alerted to several cases of pneumonia of unknown origin in Wuhan City, Hubei Province, China. The cause was found to be a novel coronavirus, SARS-CoV-2. The disease caused by this novel virus has been named COVID-19. The outbreak of COVID-19 was declared a public health emergency of international concern in January 2020. The disease has since spread, with an enormous impact on the health and well-being of individuals and populations worldwide. It has further caused major disruptions to various sectors of society and the economy across the globe.

Vaccines are a critical tool in combating the pandemic. In the rapidly evolving field of COVID-19 vaccines, WHO has issued to date interim recommendations on the use of a number of COVID-19 vaccines (4).

预览已结束, 完整报告链接和二维码如下:

https://www.yunbaogao.cn/report/index/report?reportId=5_23454





untries or

;d 18-59

ne world	following website:
1). There	https://covid19.who.int/ta
le to other	ble
COV3001 >y (95%Cl	

can be found on the